Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd.

Shenzhen Neptunus Pharmaceutical Research Insitute Co., Ltd

Xiaorou Liu

Jin Wang

Hanlin Feng

Zhiguo Wang

Tian Tang

Yanqing Wang

Jingan Yang

Jing Cui

Ruyi Jin

A pharmaceutical composition including neptinib is provided. The composition includes neptinib or a pharmaceutically acceptable salt thereof, and an excipient at a low risk of compatibleness. Furthermore, the pharmaceutical composition of the present invention may also include pharmaceutically acceptable organic acid or inorganic acid as a stabilizer. The content of impurity A maintains a non-significant increase in the long-term and accelerated stability investigation for the pharmaceutical composition.

Pharmaceutical composition comprising neptinib or salt thereof and method for controlling impurity thereof

Provided are a new tubulin inhibitor and applications thereof, the tubulin inhibitor being a series of compounds based on substituted heterocyclic skeletons, targeting the colchicine binding sites of tubulin. The structure is: Formula (I), wherein: formula (A), n independently expresses an integer between 0 and 5, the condition being that n&#x2264;5, A represents mono- or poly-substituted groups, the groups being selected from the group consisting of H, C1-C20 amide group, C1-C20 acyloxy group, C1-C20 alkanoyl group, C1-C20 alkoxycarbonyl group, C1-C20 alkoxy group, C1-C20 alkylamino group, C1-C20 alkylcarboxyamino group, aroyl group, aralkanoyl group, carboxyl group, cyano group, halogen group, hydroxyl group, nitro group and methylthienyl group. 

Tubulin inhibitor

Growing community of inventors

Guangdong, China

Xiaorou Liu